Manager TitleAgeSince
President - 2023-12-13
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap.
23-12-13Issuer sale

Chief Executive Officer

643,595 0.3411%
23-12-13Issuer sale

Chief Operating Officer

474,932 0.2517%
23-12-13Issuer sale

Director

4,585 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+1.70%+7.41%+3.12%+8.46% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +1.95%+4.85%+79.92%+120.30% 27.3B
Weighted average by Cap. +1.75%+5.65%+90.75%+137.74%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock